Evidence map›Paper›PMID 37601097›Full record

ReviewFrontiers in cell and developmental biology2023

Umbilical cord mesenchymal stem cells for regenerative treatment of intervertebral disc degeneration.

Huagui Huang, Xin Liu, Jinzuo Wang, Moran Suo, Jing Zhang, Tianze Sun, Wentao Zhang, Zhonghai Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cell and developmental biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Orthobiologic Management Options for Degenerative Disc Disease.Bioengineering (Basel, Switzerland) · 2024
    Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Huagui HuangDepartment of Orthopedics, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Xin LiuDepartment of Orthopedics, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Jinzuo WangDepartment of Orthopedics, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Moran SuoDepartment of Orthopedics, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Jing ZhangDepartment of Orthopedics, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Tianze SunDepartment of Orthopedics, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Wentao ZhangDepartment of Orthopedics, First Affiliated Hospital of Dalian Medical University, Dalian, China.
Zhonghai LiDepartment of Orthopedics, First Affiliated Hospital of Dalian Medical University, Dalian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intervertebral disc degeneration is thought to be a major contributor to low back pain, the etiology of which is complex and not yet fully understood. To compensate for the lack of drug and surgical treatment, mesenchymal stem cells have been proposed for regenerative treatment of intervertebral discs in recent years, and encouraging results have been achieved in related trials. Mesenchymal stem cells can be derived from different parts of the body, among which mesenchymal stem cells isolated from the fetal umbilical cord have excellent performance in terms of difficulty of acquisition, differentiation potential, immunogenicity and ethical risk. This makes it possible for umbilical cord derived mesenchymal stem cells to replace the most widely used bone marrow-derived and adipose tissue derived mesenchymal stem cells as the first choice for regenerating intervertebral discs. However, the survival of umbilical cord mesenchymal stem cells within the intervertebral disc is a major factor affecting their regenerative capacity. In recent years biomaterial scaffolds in tissue engineering have aided the survival of umbilical cord mesenchymal stem cells by mimicking the natural extracellular matrix. This seems to provide a new idea for the application of umbilical cord mesenchymal stem cells. This article reviews the structure of the intervertebral disc, disc degeneration, and the strengths and weaknesses of common treatment methods. We focus on the cell source, cell characteristics, mechanism of action and related experiments to summarize the umbilical cord mesenchymal stem cells and explore the feasibility of tissue engineering technology of umbilical cord mesenchymal stem cells. Hoping to provide new ideas for the treatment of disc degeneration.

Indexed as

intervertebral discintervertebral disc degenerationmesenchymal stem cellstissue engineeringumbilical cord

Identifiers

PMID37601097
PMCPMC10439242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.